Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Follow-Up Questions
Who is the CEO of Oramed Pharmaceuticals Inc?
Mr. Nadav Kidron is the Chairman of the Board of Oramed Pharmaceuticals Inc, joining the firm since 2006.
What is the price performance of ORMP stock?
The current price of ORMP is $2.44, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Oramed Pharmaceuticals Inc?
Oramed Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Oramed Pharmaceuticals Inc market cap?
Oramed Pharmaceuticals Inc's current market cap is $100.0M
Is Oramed Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Oramed Pharmaceuticals Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
